Impact of immunoadsorption on autoantibodies and physical performance in post-COVID patients: a prospective exploratory study of 18 participants
- 1Department of Internal Medicine, Division of Infectious Diseases, Nephrology, Endocrinology and Tropical Medicine, University Medical Center Rostock, Rostock, Germany
- 2Core Facility for Cell Sorting and Cell Analysis, University Medical Center Rostock, Rostock, Germany
Abstract
Purpose: Autoantibodies against β-adrenergic and muscarinic acetylcholine receptors are said to play a role in the pathophysiology of post-COVID syndrome. To date, only a limited number of studies have investigated the effectiveness of immunoadsorption. This prospective exploratory study investigates the effectiveness of immunoadsorption by assessing reductions in autoantibody levels and improvements in physical performance.
Methods: In a prospective exploratory clinical trial, 18 patients with post-COVID syndrome and elevated levels of antibodies against β1/β2-adrenergic receptors and/or M3/M4-muscarinic acetylcholine receptors were treated with a course of five consecutive immunoadsorption sessions. Clinical assessments, objective functional performance tests (e.g., step counters), laboratory parameters, and self-reported performance were performed during the study.
Results: A total of 15 women and 3 men were included in the study. Immunoadsorption was well tolerated. All participants showed a significant reduction in circulating antibodies against β1/β2-adrenergic receptors and M3/M4-muscarinic acetylcholine receptors; however, these levels returned to baseline within the following 3 to 6 months. Objective determinations of physical performance showed no significant improvement following immunoadsorption. Self-reported evaluation revealed a slight improvement in pain and fatigue. However, the correlation analysis failed to demonstrate a significant association between changes in autoantibody levels and subjectively perceived symptoms.
Conclusion: Immunoadsorption was safe and resulted in a short-term, significant reduction in measured autoantibodies. However, there were no improvements in objectively measured performance. Our results indicate that immunoadsorption is not an effective approach for patients with post-COVID syndrome.
Related
- Comparative outcomes of conventional follitropin delta 15 µg/day versus follitropin alfa 225 IU/day for ovarian stimulation: results from an exploratory post hoc analysis of Spanish participants from the ADAPT-1 randomized controlled trial
- PROTEOMIC IDENTIFICATION OF NOVEL AUTOANTIBODY TARGETS IN RHEUMATOID ARTHRITIS AND DIAGNOSTIC PERFORMANCE OF TGF-BETA-1-INDUCED PROTEIN AND SERUM AMYLOID A AUTOANTIBODIES
- Assessing hemodynamic responses in patients undergoing oral surgery with vasoconstrictor-enhanced local anesthesia: a prospective comparative study between medically compromised and healthy participants
- Renin-Angiotensin System Inhibitor Use and Cancer Incidence Among UK Biobank Participants: A Prospective Cohort Study.
- Is adherence to the 24-hour movement guidelines related to a lower risk of cardiovascular events? A prospective cohort study including 13 897 participants from the SUN project.
BibTeX
@article{wossidlo2026impact,
title = {{Impact of immunoadsorption on autoantibodies and physical performance in post-COVID patients: a prospective exploratory study of 18 participants}},
author = {Christine Wossidlo and Felix Steinbeck and Hilte Geerdes-Fenge and Martina Sombetzki and Steffen Mitzner and Micha Loebermann and Emil C. Reisinger and Sebastian Koball},
journal = {Infection},
year = {2026},
month = aug,
doi = {10.1007/s15010-026-02914-8},
url = {https://doi.org/10.1007/s15010-026-02914-8},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Impact of immunoadsorption on autoantibodies and physical performance in post-COVID patients: a prospective exploratory study of 18 participants
AU - Christine Wossidlo
AU - Felix Steinbeck
AU - Hilte Geerdes-Fenge
AU - Martina Sombetzki
AU - Steffen Mitzner
AU - Micha Loebermann
AU - Emil C. Reisinger
AU - Sebastian Koball
PY - 2026
DA - 2026/08/11
JO - Infection
DO - 10.1007/s15010-026-02914-8
UR - https://doi.org/10.1007/s15010-026-02914-8
AB - Purpose: Autoantibodies against β-adrenergic and muscarinic acetylcholine receptors are said to play a role in the pathophysiology of post-COVID syndrome. To date, only a limited number of studies have investigated the effectiveness of immunoadsorption. This prospective exploratory study investigates the effectiveness of immunoadsorption by assessing reductions in autoantibody levels and improvements in physical performance. Methods: In a prospective exploratory clinical trial, 18 patients with post-COVID syndrome and elevated levels of antibodies against β1/β2-adrenergic receptors and/or M3/M4-muscarinic acetylcholine receptors were treated with a course of five consecutive immunoadsorption sessions. Clinical assessments, objective functional performance tests (e.g., step counters), laboratory parameters, and self-reported performance were performed during the study. Results: A total of 15 women and 3 men were included in the study. Immunoadsorption was well tolerated. All participants showed a significant reduction in circulating antibodies against β1/β2-adrenergic receptors and M3/M4-muscarinic acetylcholine receptors; however, these levels returned to baseline within the following 3 to 6 months. Objective determinations of physical performance showed no significant improvement following immunoadsorption. Self-reported evaluation revealed a slight improvement in pain and fatigue. However, the correlation analysis failed to demonstrate a significant association between changes in autoantibody levels and subjectively perceived symptoms. Conclusion: Immunoadsorption was safe and resulted in a short-term, significant reduction in measured autoantibodies. However, there were no improvements in objectively measured performance. Our results indicate that immunoadsorption is not an effective approach for patients with post-COVID syndrome.
SN - 0300-8126
SN - 1439-0973
ER -